Claims Scope:

Patent issued June 2, 2021. 

Sequence-specific guide+ backbone 

• 80% identity to SIN 31 (CCR5, Vif at Tat) (Gd+Bb)  
• 90% identity to SIN 1, 2, & 3 (mir30 CCR5, mir21 Vif, and mir185 Tat, any order) (Gd+Bb) 
• Compositions (LV vector, LV particle, modified cell) & method of treating cells infected with HIV (broadest method claims agnostic to pre-immunized state; dependent claims include pre-immunization)